Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Nedra Johnson"'
Autor:
Lubna Naaz Chaudhary, Julie Jorns, Yunguang Sun, Yee Chung Cheng, Sailaja Kamaraju, John Burfeind, MaryBeth Gonyo, Amanda Kong, Caitlin Patten, Tina Yen, Chandler Cortina, Ebony Carson, Nedra Johnson, Carmen Bergom, Shirng-Wern Tsaih, Anjishnu Banerjee, Yu Wang, Inna Chervoneva, Elizabeth Weil, Christopher R Chitambar, Hallgeir Rui
Background. Endocrine resistant metastatic disease develops in ~20-25% of hormone-receptor positive (HR+) breast cancer (BC) patients despite endocrine therapy (ET) use. Upregulation of HER family receptor tyrosine kinases (RTKs) represent escape mec
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::248a572849afe55c1fb5987de5c5fd37
https://doi.org/10.21203/rs.3.rs-2777910/v1
https://doi.org/10.21203/rs.3.rs-2777910/v1
Autor:
Lubna Naaz Chaudhary, Julie M Jorns, Yee Chung Cheng, Sailaja Kamaraju, John Burfeind, Mary Beth Gonyo, Amanda Kong, Caitlin Patten, Tina Yen, Chandler Cortina, Ebony Carson, Nedra Johnson, Carmen Bergom, Anjishnu Banerjee, Yu Wang, Yunguang Sun, Christopher R Chitambar, Hallgeir Rui
Publikováno v:
Cancer Research. 82:P4-02
Background: Patients with hormone receptor-positive (HR+) breast cancer (BC) experience significant improvement in long-term outcomes with endocrine therapy (ET). However, metastatic recurrences of endocrine resistant disease develop in about 20-25%
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1353b930a9036841bfe2cd6eeaec2df2
https://doi.org/10.1158/1538-7445.sabcs21-p4-02-03
https://doi.org/10.1158/1538-7445.sabcs21-p4-02-03
Autor:
Caitlin R. Patten, Ebony Carson, Chandler S. Cortina, Yu Wang, Carmen Bergom, Hallgeir Rui, Yee Chung Cheng, Mary Beth Gonyo, Nedra Johnson, Julie M. Jorns, Amanda L. Kong, Anjishnu Banerjee, Lubna N Chaudhary, Christopher R. Chitambar, Tina W.F. Yen, Sailaja Kamaraju
Publikováno v:
Cancer Research. 81:PD7-07
Background: Endocrine therapy provides significant improvement in the long-term outcomes of patients with hormone receptor-positive (HR+) breast cancer (BC). However, metastatic recurrences of endocrine resistant disease develop in about 20-25% of pa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7c326de1bc5eac787a4101be4940eb13
https://doi.org/10.1158/1538-7445.sabcs20-pd7-07
https://doi.org/10.1158/1538-7445.sabcs20-pd7-07